<p>2025 年 11 月 13 日- 下午 01:10</p>
<p><strong><em>“種子與增強” 方法具有突破潛力，準備改變癌症免疫療法的格局</em></strong></p>
<p>新加坡--(商業資訊)--ImmunoScape Pte. Ltd.是一家由 A*STAR 孵化的公司，得到安進風險投資和新加坡經濟發展局的支持，正在開發下一代基於 T 細胞受體（TCR）的癌症免疫療法。今天，該公司宣佈與 Cue Biopharma Inc.（納斯達克：CUE）達成獨家許可協議，主導開發一種新型療法，以攻擊實體腫瘤癌症。該協議為 ImmunoScape 提供了對 Cue Biopharma 在腫瘤學領域的臨牀階段 Immuno-STAT®分子的獨家訪問權。</p>
<p>通過將 Cue Biopharma 的技術與其精準 T 細胞受體（TCR）療法相結合，ImmunoScape 正在開創一種新的 “種子與增強” 免疫療法，解決當前細胞療法的不足之處，使注入的腫瘤靶向 T 細胞能夠在體內有效擴展——以受控的方式在患者體內產生大量高效的腫瘤殺傷 T 細胞。</p>
<p>該策略使用患者自身 T 細胞的最小劑量，經過腫瘤特異性 TCR 工程化（種子），隨後定期施用攜帶 Immuno-STAT®分子的 TCR 匹配和白細胞介素-2（IL-2）（增強）。這種組合免疫療法首次實現了 IL-2 的真實治療指數，通過選擇性地將其遞送到腫瘤反應性 T 細胞，從而消除全身細胞因子毒性，簡化生產流程，並可能對惡性細胞進行更深層次、更持久的攻擊。</p>
<p><strong>ImmunoScape 的臨牀項目針對高未滿足醫療需求的癌症</strong></p>
<p>ImmunoScape 的首個種子與增強項目針對 WT1 抗原，該抗原在許多頑固的實體腫瘤中表達——包括肺癌、胰腺癌、結直腸癌、卵巢癌、胃癌、黑色素瘤以及頭頸癌——以及某些血液惡性腫瘤，這些癌症仍然代表着顯著的未滿足臨牀需求。ImmunoScape 在新加坡的實驗室在多個實體腫瘤模型中生成了引人注目的臨牀前數據，這些數據支持 IND 啓用研究，預計將在 2027 年開始臨牀試驗。</p>
<p>“我們在新加坡的體內癌症模型展示了這種新方法在多種實體腫瘤中的有效性，” ImmunoScape 的發現副總裁 Dr. Kar Wai Tan 博士説。</p>
<p>公司的模塊化種子與增強平台技術有潛力通過提供安全、耐受性良好且有效的癌症療法來改變細胞療法，同時簡化患者的治療過程。除了針對實體腫瘤，該平台還可以用於增強現有的經典自體和體內 T 細胞療法。ImmunoScape 的臨牀研究將包括與亞洲人羣相關的癌症和免疫類型。</p>
<p>“ImmunoScape 正在開創下一波癌症治療，” ImmunoScape 的首席執行官 Michael Fehlings 博士説。“通過我們的下一代種子與增強策略，我們旨在在多種癌症中提供臨牀上有意義的患者結果改善。”</p>
<p><strong>ImmunoScape 通過關鍵任命加強領導層</strong></p>
<p>在轉型為全球癌症免疫療法開發領導者的過程中，ImmunoScape 很高興地宣佈對其領導結構的補充：</p>
<ul>
<li><strong>Usman &#34;Oz&#34; Azam, MD，加入董事會：</strong> Azam 博士是 Cue Biopharma 的總裁兼首席執行官，曾擔任諾華細胞和基因治療業務的全球負責人，帶來了波士頓的 Cue Biopharma 的支持和在細胞療法開發、生產和商業化方面的豐富經驗。Azam 博士曾擔任 Inspirna, Inc.的首席執行官，該公司是一家專注於新型癌症藥物發現和開發的私營臨牀階段生物製藥公司，並曾擔任 Tmunity Therapeutics 的總裁兼首席執行官，參與開發用於實體腫瘤應用的基因工程 CAR-T 細胞療法。</li>
</ul>
<ul>
<li><strong>Adrian Bot, MD/PhD，加入董事會：</strong> Bot 博士在免疫療法的發現、開發和商業化方面擁有 27 年的經驗，包括 CAR 和 TCR 工程化 T 細胞產品。他是 Capstan Therapeutics 的創始首席科學官，專注於體內 CAR 療法，並曾擔任 Kite Pharma 的首席科學官和全球轉化醫學與研究負責人，開發開創性的基因工程 T 細胞療法。</li>
</ul>
<p>“實體腫瘤中的免疫療法正處於一個關鍵時刻，需要複雜的精準醫學工具來有效地協調持久的臨牀反應。我相信 ImmunoScape 的新型免疫治療工具將推動癌症患者在廣泛癌症類型中的需求得到更好的滿足。他們的創新種子與增強方法在癌症領域具有全球意義，” Bot 博士説。</p>
<ul>
<li><strong>Pamela Munster, MD，加入科學顧問委員會：</strong> Pamela Munster 博士是一位傑出的醫學腫瘤學家，擔任 UCSF 早期階段腫瘤臨牀試驗項目的主任，加入並補充了科學顧問委員會現有的專家，帶來了對未滿足實體腫瘤患者需求的無與倫比的臨牀見解。Munster 博士是獲獎書籍《扭轉命運：我與 BRCA 的旅程——從乳腺癌醫生到患者再到醫生》的作者。</li>
</ul>
<p><strong>一家得到本地和全球合作伙伴支持的新加坡生物科技公司</strong></p>
<p>ImmunoScape 感謝其早期合作伙伴和投資者使這一開創性工作成為可能。該公司還感謝 A*STAR 提供的基礎研究支持，以及新加坡企業發展局和新加坡經濟發展局（EDB）對支持公司新加坡運營的承諾。該公司感謝其財務投資者，包括 EDB Investments、Amgen Ventures 和 Anzu Partners 對其平台和使命的共同信念。</p>
<p><strong>關於 ImmunoScape</strong></p>
<p>ImmunoScape 是一家總部位於新加坡的頂尖臨牀階段生物技術公司，專注於發現和開發下一代腫瘤細胞免疫療法。ImmunoScape 在新加坡和加利福尼亞開展業務，推動創新，以提供針對實體腫瘤的變革性治療。欲瞭解更多信息，請訪問 <strong>immunoscape.com</strong>。</p>
<p><strong>關於 Cue Biopharma</strong></p>
<p>Cue Biopharma 是一家臨牀階段的生物製藥公司，開發一種新型可注射生物製劑，旨在直接在患者體內選擇性地激活和調節特定疾病的 T 細胞。該公司的專有平台 Immuno-STAT® <em>(選擇性靶向和改變 T 細胞)</em> 和生物製劑旨在利用身體內在免疫系統的治癒潛力，而不產生廣泛系統性免疫調節的副作用。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNjg4NTVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNjg4NTVyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251113268855/en/</p>
<p><strong>ImmunoScape 媒體聯繫人</strong></p>
<p>Kalyn Schieffer</p>
<p>公關負責人</p>
<p>Anzu Partners 為 ImmunoScape 提供服務</p>
<p>kos@anzupartners.com</p>
<p>Cue Biopharma 投資者聯繫人</p>
<p>Marie Campinell</p>
<p>企業傳播高級總監</p>
<p>Cue Biopharma, Inc.</p>
<p>mcampinell@cuebio.com</p>
<p>Cue Biopharma 媒體聯繫人</p>
<p>Jonathan Pappas</p>
<p>LifeSci Communications</p>
<p>jpappas@lifescicomms.com</p>
<p>來源：ImmunoScape Pte. Ltd.</p>

<p>新加坡生物科技公司 ImmunoScape Pte. Ltd.宣佈與 Cue Biopharma 達成獨家許可協議，開發針對實體腫瘤的下一代細胞療法，採用 “種子與增強” 方法。該公司還通過關鍵任命加強了領導層，包括 Usman Azam 和 Adrian Bot 加入董事會，以及 Pamela Munster 加入科學顧問委員會。這一戰略舉措旨在轉變癌症免疫療法，並解決實體腫瘤未滿足的醫療需求</p>

<p>11/13/2025 - 01:10 PM</p>
<div class="lb-trans"><p>2025 年 11 月 13 日- 下午 01:10</p>
</div><p><strong><em>“Seed-and-Boost” Approach with Breakthrough Potential, Poised to Transform the Cancer Immunotherapy Landscape</em></strong></p>
<div class="lb-trans"><p><strong><em>“種子與增強” 方法具有突破潛力，準備改變癌症免疫療法的格局</em></strong></p>
</div><p>SINGAPORE--(BUSINESS WIRE)--ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based cancer immunotherapies, today announced an exclusive in-licensing deal with Cue Biopharma Inc. (Nasdaq: CUE) to lead the development of a distinct new class of therapies to attack solid tumor cancers. The deal provides ImmunoScape with exclusive access to Cue Biopharma’s clinical-stage Immuno-STAT® molecules in oncology.</p>
<div class="lb-trans"><p>新加坡--(商業資訊)--ImmunoScape Pte. Ltd.是一家由 A*STAR 孵化的公司，得到安進風險投資和新加坡經濟發展局的支持，正在開發下一代基於 T 細胞受體（TCR）的癌症免疫療法。今天，該公司宣佈與 Cue Biopharma Inc.（納斯達克：CUE）達成獨家許可協議，主導開發一種新型療法，以攻擊實體腫瘤癌症。該協議為 ImmunoScape 提供了對 Cue Biopharma 在腫瘤學領域的臨牀階段 Immuno-STAT®分子的獨家訪問權。</p>
</div><p>By combining Cue Biopharma’s technology with its precision T cell receptor (TCR) therapy, ImmunoScape is pioneering a new “Seed-and-Boost” approach to immunotherapy, that addresses the shortcomings of current cell therapies by enabling potent <em>in vivo</em> expansion of infused tumor targeting T-cells—producing large numbers of highly effective tumor killing T cells in a controlled manner in the patient.</p>
<div class="lb-trans"><p>通過將 Cue Biopharma 的技術與其精準 T 細胞受體（TCR）療法相結合，ImmunoScape 正在開創一種新的 “種子與增強” 免疫療法，解決當前細胞療法的不足之處，使注入的腫瘤靶向 T 細胞能夠在體內有效擴展——以受控的方式在患者體內產生大量高效的腫瘤殺傷 T 細胞。</p>
</div><p>The strategy uses a minimal dose of the patient’s own T cells, engineered with a tumor-specific TCR (Seed), followed by periodic administration of TCR-matching and interleukin-2 (IL-2) carrying Immuno-STAT® molecules (Boost). This combination immunotherapy enables, for the first time, the establishment of a true therapeutic index for IL-2 by selectively delivering it to tumor-reactive T cells. The potential breakthrough approach offers to eliminate systemic cytokine toxicity, streamline manufacturing, and may deliver a deeper, more durable attack on malignant cells.</p>
<div class="lb-trans"><p>該策略使用患者自身 T 細胞的最小劑量，經過腫瘤特異性 TCR 工程化（種子），隨後定期施用攜帶 Immuno-STAT®分子的 TCR 匹配和白細胞介素-2（IL-2）（增強）。這種組合免疫療法首次實現了 IL-2 的真實治療指數，通過選擇性地將其遞送到腫瘤反應性 T 細胞，從而消除全身細胞因子毒性，簡化生產流程，並可能對惡性細胞進行更深層次、更持久的攻擊。</p>
</div><p><strong>ImmunoScape’s clinical program targets cancers of high unmet medical need</strong></p>
<div class="lb-trans"><p><strong>ImmunoScape 的臨牀項目針對高未滿足醫療需求的癌症</strong></p>
</div><p>ImmunoScape’s first Seed-and-Boost program targets the WT1 antigen, which is expressed across many recalcitrant solid tumors — including lung, pancreatic, colorectal, ovarian, gastric, melanoma, and head and neck cancers — as well as certain hematologic malignancies that still represent significant unmet clinical needs. ImmunoScape’s Singapore lab has generated compelling preclinical data across multiple solid tumor models, which is supportive of IND-enabling studies that will enable clinical trials to commence by 2027.</p>
<div class="lb-trans"><p>ImmunoScape 的首個種子與增強項目針對 WT1 抗原，該抗原在許多頑固的實體腫瘤中表達——包括肺癌、胰腺癌、結直腸癌、卵巢癌、胃癌、黑色素瘤以及頭頸癌——以及某些血液惡性腫瘤，這些癌症仍然代表着顯著的未滿足臨牀需求。ImmunoScape 在新加坡的實驗室在多個實體腫瘤模型中生成了引人注目的臨牀前數據，這些數據支持 IND 啓用研究，預計將在 2027 年開始臨牀試驗。</p>
</div><p>“Our Singapore-based in vivo cancer models demonstrate the efficacy of this new approach in multiple solid tumors” said Dr. Kar Wai Tan PhD, ImmunoScape’s Vice President of Discovery.</p>
<div class="lb-trans"><p>“我們在新加坡的體內癌症模型展示了這種新方法在多種實體腫瘤中的有效性，” ImmunoScape 的發現副總裁 Dr. Kar Wai Tan 博士説。</p>
</div><p>The Company’s modular Seed-and-Boost platform technology has the potential to transform cell therapy, through the delivery of safe, tolerable and effective therapies against cancer while simplifying the patient journey. In addition to targeting solid tumors, the platform may also be used to enhance existing classic autologous and in vivo T cell therapies. ImmunoScape’s clinical studies will include cancers and immune types that are relevant to Asian populations.</p>
<div class="lb-trans"><p>公司的模塊化種子與增強平台技術有潛力通過提供安全、耐受性良好且有效的癌症療法來改變細胞療法，同時簡化患者的治療過程。除了針對實體腫瘤，該平台還可以用於增強現有的經典自體和體內 T 細胞療法。ImmunoScape 的臨牀研究將包括與亞洲人羣相關的癌症和免疫類型。</p>
</div><p>“ImmunoScape is pioneering the next wave of cancer therapeutics,” said Michael Fehlings, PhD, CEO of ImmunoScape. “Through our next-generation Seed-and-Boost strategy, we aim to deliver clinically meaningful improvements in patient outcomes in multiple cancers.”</p>
<div class="lb-trans"><p>“ImmunoScape 正在開創下一波癌症治療，” ImmunoScape 的首席執行官 Michael Fehlings 博士説。“通過我們的下一代種子與增強策略，我們旨在在多種癌症中提供臨牀上有意義的患者結果改善。”</p>
</div><p><strong>ImmunoScape Strengthens Leadership with Key Appointments</strong></p>
<div class="lb-trans"><p><strong>ImmunoScape 通過關鍵任命加強領導層</strong></p>
</div><p>As it transitions to becoming a global leader in cancer immunotherapy development, ImmunoScape is pleased to announce additions to its leadership structure:</p>
<div class="lb-trans"><p>在轉型為全球癌症免疫療法開發領導者的過程中，ImmunoScape 很高興地宣佈對其領導結構的補充：</p>
</div><ul>
<li><strong>Usman &#34;Oz&#34; Azam, MD, Joins the Board of Directors:</strong> Dr. Azam, President and CEO of Cue Biopharma and former global head of Novartis' Cell and Gene Therapy business, brings the support of Boston-based Cue Biopharma and extensive expertise in cell therapy development, manufacturing and commercialization. Dr. Azam served as Chief Executive Officer of Inspirna, Inc., a privately held clinical stage biopharmaceutical company focused on the discovery and development of novel cancer drugs and President and CEO of Tmunity Therapeutics, where he was involved in developing genetically engineered CAR-T cell therapies for solid tumor applications in cancer.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Usman &#34;Oz&#34; Azam, MD，加入董事會：</strong> Azam 博士是 Cue Biopharma 的總裁兼首席執行官，曾擔任諾華細胞和基因治療業務的全球負責人，帶來了波士頓的 Cue Biopharma 的支持和在細胞療法開發、生產和商業化方面的豐富經驗。Azam 博士曾擔任 Inspirna, Inc.的首席執行官，該公司是一家專注於新型癌症藥物發現和開發的私營臨牀階段生物製藥公司，並曾擔任 Tmunity Therapeutics 的總裁兼首席執行官，參與開發用於實體腫瘤應用的基因工程 CAR-T 細胞療法。</li>
</ul>
</div><ul>
<li><strong>Adrian Bot, MD/PhD, Joins the Board of Directors:</strong> Dr. Bot brings 27 years of experience in discovery, development and commercialization of immunotherapies including CAR and TCR-engineered T cell products. He was the founding CSO for Capstan Therapeutics focused on in vivo CAR therapies and has held leadership positions including CSO and Global Head of Translational Medicine and Research at Kite Pharma developing groundbreaking gene engineered T cell therapies.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Adrian Bot, MD/PhD，加入董事會：</strong> Bot 博士在免疫療法的發現、開發和商業化方面擁有 27 年的經驗，包括 CAR 和 TCR 工程化 T 細胞產品。他是 Capstan Therapeutics 的創始首席科學官，專注於體內 CAR 療法，並曾擔任 Kite Pharma 的首席科學官和全球轉化醫學與研究負責人，開發開創性的基因工程 T 細胞療法。</li>
</ul>
</div><p>“Immunotherapy in solid tumors is at a juncture, when sophisticated, precision medicine tools are needed to effectively orchestrate a durable clinical response, I am convinced that the novel immunotherapeutic tools of ImmunoScape will push the boundaries towards better addressing the needs of cancer patients in a broad range of cancer types. Their innovative Seed and Boost approach is of global significance in the cancer field,” said Dr. Bot.</p>
<div class="lb-trans"><p>“實體腫瘤中的免疫療法正處於一個關鍵時刻，需要複雜的精準醫學工具來有效地協調持久的臨牀反應。我相信 ImmunoScape 的新型免疫治療工具將推動癌症患者在廣泛癌症類型中的需求得到更好的滿足。他們的創新種子與增強方法在癌症領域具有全球意義，” Bot 博士説。</p>
</div><ul>
<li><strong>Pamela Munster, MD, Joins Scientific Advisory Board:</strong> Dr. Pamela Munster, a distinguished medical oncologist and Director of the early-stage oncology clinical trials program at UCSF, joins and complements the existing experts on the Scientific Advisory Board, bringing unparalleled clinical insights into unmet solid tumor patient needs. Dr. Munster is the author of the award-winning book, <em>Twisting Fate: My Journey with BRCA―from Breast Cancer Doctor to Patient and Back</em>.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Pamela Munster, MD，加入科學顧問委員會：</strong> Pamela Munster 博士是一位傑出的醫學腫瘤學家，擔任 UCSF 早期階段腫瘤臨牀試驗項目的主任，加入並補充了科學顧問委員會現有的專家，帶來了對未滿足實體腫瘤患者需求的無與倫比的臨牀見解。Munster 博士是獲獎書籍《扭轉命運：我與 BRCA 的旅程——從乳腺癌醫生到患者再到醫生》的作者。</li>
</ul>
</div><p><strong>A Singapore Biotech Supported by Local and Global Partners</strong></p>
<div class="lb-trans"><p><strong>一家得到本地和全球合作伙伴支持的新加坡生物科技公司</strong></p>
</div><p>ImmunoScape thanks its early partners and investors for making this pioneering work possible. The company is, additionally, grateful to A*STAR for foundational research support, and Enterprise Singapore and the Singapore Economic Development Board (EDB) for their commitment to supporting the company’s Singapore operations. The company thanks its financial investors, including EDB Investments, Amgen Ventures, and Anzu Partners for their shared belief in its platform and mission.</p>
<div class="lb-trans"><p>ImmunoScape 感謝其早期合作伙伴和投資者使這一開創性工作成為可能。該公司還感謝 A*STAR 提供的基礎研究支持，以及新加坡企業發展局和新加坡經濟發展局（EDB）對支持公司新加坡運營的承諾。該公司感謝其財務投資者，包括 EDB Investments、Amgen Ventures 和 Anzu Partners 對其平台和使命的共同信念。</p>
</div><p><strong>About ImmunoScape</strong></p>
<div class="lb-trans"><p><strong>關於 ImmunoScape</strong></p>
</div><p>ImmunoScape is a premier, clinical-stage Singapore-headquartered biotechnology company focused on the discovery and development of next-generation cell immunotherapies in oncology. With operations in Singapore and California, ImmunoScape drives innovation to deliver transformative treatments for solid tumors. For more information, please visit <strong>immunoscape.com</strong>.</p>
<div class="lb-trans"><p>ImmunoScape 是一家總部位於新加坡的頂尖臨牀階段生物技術公司，專注於發現和開發下一代腫瘤細胞免疫療法。ImmunoScape 在新加坡和加利福尼亞開展業務，推動創新，以提供針對實體腫瘤的變革性治療。欲瞭解更多信息，請訪問 <strong>immunoscape.com</strong>。</p>
</div><p><strong>About Cue Biopharma</strong></p>
<div class="lb-trans"><p><strong>關於 Cue Biopharma</strong></p>
</div><p>Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT® <em>(Selective Targeting and Alteration of T cells)</em>, and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation.</p>
<div class="lb-trans"><p>Cue Biopharma 是一家臨牀階段的生物製藥公司，開發一種新型可注射生物製劑，旨在直接在患者體內選擇性地激活和調節特定疾病的 T 細胞。該公司的專有平台 Immuno-STAT® <em>(選擇性靶向和改變 T 細胞)</em> 和生物製劑旨在利用身體內在免疫系統的治癒潛力，而不產生廣泛系統性免疫調節的副作用。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNjg4NTVyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251113268855r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251113268855/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251113268855/en/</p>
</div><p><strong>ImmunoScape Media Contact</strong></p>
<div class="lb-trans"><p><strong>ImmunoScape 媒體聯繫人</strong></p>
</div><p>Kalyn Schieffer</p>
<div class="lb-trans"><p>Kalyn Schieffer</p>
</div><p>Principal, Public Relations</p>
<div class="lb-trans"><p>公關負責人</p>
</div><p>Anzu Partners for ImmunoScape</p>
<div class="lb-trans"><p>Anzu Partners 為 ImmunoScape 提供服務</p>
</div><p>kos@anzupartners.com</p>
<div class="lb-trans"><p>kos@anzupartners.com</p>
</div><p>Investor Contact for Cue Biopharma</p>
<div class="lb-trans"><p>Cue Biopharma 投資者聯繫人</p>
</div><p>Marie Campinell</p>
<div class="lb-trans"><p>Marie Campinell</p>
</div><p>Senior Director, Corporate Communications</p>
<div class="lb-trans"><p>企業傳播高級總監</p>
</div><p>Cue Biopharma, Inc.</p>
<div class="lb-trans"><p>Cue Biopharma, Inc.</p>
</div><p>mcampinell@cuebio.com</p>
<div class="lb-trans"><p>mcampinell@cuebio.com</p>
</div><p>Media Contact for Cue Biopharma</p>
<div class="lb-trans"><p>Cue Biopharma 媒體聯繫人</p>
</div><p>Jonathan Pappas</p>
<div class="lb-trans"><p>Jonathan Pappas</p>
</div><p>LifeSci Communications</p>
<div class="lb-trans"><p>LifeSci Communications</p>
</div><p>jpappas@lifescicomms.com</p>
<div class="lb-trans"><p>jpappas@lifescicomms.com</p>
</div><p>Source: ImmunoScape Pte. Ltd.</p>
<div class="lb-trans"><p>來源：ImmunoScape Pte. Ltd.</p>
</div>

Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments | CUE Stock News

總部位於新加坡的 ImmunoScape 公司在實體瘤的下一代細胞療法領域開創了先河；宣佈達成重要的許可協議，並任命了新的董事會成員和科學顧問委員會成員 | Cue BioPharma 股票新聞